Fermer le menu

Member of Lyonbiopole


Mablink Bioscience is a biotechnology company wholly owned subsidiary of Eli Lilly since December 2023 and developing next-generation Antibody-Drug-Conjugates (ADC) based on a proprietary drug-linker platform technology. Its drug-linker technology delivers ADCs with a high payload (DAR of 8-16) that are homogeneous and plasma-stable,without negative impact on aggregation, with improved pharmacokinetics, in a timely and cost-effective manner. With its technology platform, Mablink is democratizing the use of next-generation ADC in the clinic, to improve patient care in the immuno-oncolgy field.


Strategic application domain: Human Medicine

Application market: Oncology

Type of activity: Technology provider, Therapeutics, Pharma or Biotech

Technologies: Antibodies - Protein - Peptide, Others

Created on dec. 5th, 2018 - 32 employees



31 rue Gorge de Loup
Immeuble Cap 9
2 rue de la Fraternelle 69009 Lyon



Vous devez être connecté et membre de Lyonbiopôle pour voir les contacts.